Gender-dependent association of the GNAS1 T393C polymorphism with early aseptic loosening after total hip arthroplasty
Corresponding Author
Hagen S. Bachmann
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany; (T: +49 201 723 3459; F: +49 201 723 5968).Search for more papers by this authorSandra Hanenkamp
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany
Department of Orthopaedic Surgery, Medical Faculty, University of Duisburg-Essen, Essen, Germany
Search for more papers by this authorBartlomiej Kornacki
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany
Department of Orthopaedic Surgery, Medical Faculty, University of Duisburg-Essen, Essen, Germany
Search for more papers by this authorUlrich H. Frey
Clinic of Anaesthesiology, Medical Faculty, University of Duisburg-Essen, Essen, Germany
Search for more papers by this authorMaja Bau
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany
Search for more papers by this authorWinfried Siffert
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany
Search for more papers by this authorChristian Wedemeyer
Department of Orthopaedic Surgery, Medical Faculty, University of Duisburg-Essen, Essen, Germany
Search for more papers by this authorCorresponding Author
Hagen S. Bachmann
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany; (T: +49 201 723 3459; F: +49 201 723 5968).Search for more papers by this authorSandra Hanenkamp
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany
Department of Orthopaedic Surgery, Medical Faculty, University of Duisburg-Essen, Essen, Germany
Search for more papers by this authorBartlomiej Kornacki
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany
Department of Orthopaedic Surgery, Medical Faculty, University of Duisburg-Essen, Essen, Germany
Search for more papers by this authorUlrich H. Frey
Clinic of Anaesthesiology, Medical Faculty, University of Duisburg-Essen, Essen, Germany
Search for more papers by this authorMaja Bau
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany
Search for more papers by this authorWinfried Siffert
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, D-45147 Essen, Germany
Search for more papers by this authorChristian Wedemeyer
Department of Orthopaedic Surgery, Medical Faculty, University of Duisburg-Essen, Essen, Germany
Search for more papers by this authorAbstract
The G-protein Gαs is involved in the physiology and pathophysiology of bone. Especially, Gαs is a key regulator of interleukin-6, which is a potent promoter of aseptic loosening. We hypothesized that the common single nucleotide polymorphism GNAS1 T393C could also affect time to aseptic loosening. Caucasian patients were genotyped for the GNAS1 T393C polymorphism. Time and median time to aseptic loosening were analyzed for dependency on GNAS1 genotypes. Time and median time were not significantly associated with genotypes. Additional analysis corrected for gender revealed, that the TT genotype was associated with significantly longer time (p = 0.048) as well as median time (p = 0.022) to aseptic loosening in female patients. In contrast to the findings in females, male TT genotype carriers had significantly shorter time (p = 0.018) and median time (p = 0.023) to aseptic loosening. Compared with TT genotype carriers heterozygous patients had a 6.25-fold lower risk with a hazard ratio of 0.160 (p = 0.016) and male patients carrying the CC genotype had an 11-fold lower risk with a hazard ratio of 0.088 (p = 0.006) in multivariate analysis. The present study suggests a significant gender-dependent role of the T393C polymorphism in aseptic loosening. The apparently contradictory results in women and men and the finding that the GNAS1 T393C genotype is an independent factor for time to aseptic loosening in male patients assigned this polymorphism as an interesting target for further investigations in bone diseases. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res
REFERENCES
- 1 Silva MJ, Sandell LJ. 2002. What's new in orthopaedic research. J Bone Joint Surg Am 84-A: 1490–1496.
- 2 Berry DJ, Harmsen WS, Cabanela ME, et al. 2002. Twenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements: factors affecting survivorship of acetabular and femoral components. J Bone Joint Surg Am 84-A: 171–177.
- 3 Flugsrud GB, Nordsletten L, Espehaug B, et al. 2007. The effect of middle-age body weight and physical activity on the risk of early revision hip arthroplasty: a cohort study of 1,535 individuals. Acta Orthop 78: 99–107.
- 4 Fuchs S, Wieder J. 2000. Survival rate of the cemented Charnley total hip endoprosthesis and modifying parameters. Biomed Tech (Berl) 45: 362–369.
- 5 Wendelboe AM, Hegmann KT, Biggs JJ, et al. 2003. Relationships between body mass indices and surgical replacements of knee and hip joints. Am J Prev Med 25: 290–295.
- 6 Matthews JB, Green TR, Stone MH, et al. 2000. Comparison of the response of primary human peripheral blood mononuclear phagocytes from different donors to challenge with model polyethylene particles of known size and dose. Biomaterials 21: 2033–2044.
- 7 Matthews JB, Besong AA, Green TR, et al. 2000. Evaluation of the response of primary human peripheral blood mononuclear phagocytes to challenge with in vitro generated clinically relevant UHMWPE particles of known size and dose. J Biomed Mater Res 52: 296–307.
- 8 Malik MH, Jury F, Bayat A, et al. 2007. Genetic susceptibility to total hip replacement failure—preliminary study on the influence of matrix metalloproteinase-1, interleukin-6 and vitamin D receptor polymorphisms. Ann Rheum Dis 66: 1116–1120.
- 9 Kolundzic R, Orlic D, Trkulja V, et al. 2006. Single nucleotide polymorphisms in the interleukin-6 gene promoter, tumor necrosis factor-alpha gene promoter, and transforming growth factor-beta1 gene signal sequence as predictors of time to onset of aseptic loosening after total hip arthroplasty: preliminary study. J Orthop Sci 11: 592–600.
- 10 Wilkinson JM, Wilson AG, Stockley I, et al. 2003. Variation in the TNF gene promoter and risk of osteolysis after total hip arthroplasty. J Bone Miner Res 18: 1995–2001.
- 11 Wettschureck N, Offermanns S. 2005. Mammalian G Proteins and their cell type specific functions. Physiol Rev 85: 1159–1204.
- 12 Weinstein LS, Liu J, Sakamoto A, et al. 2004. Minireview: GNAS: normal and abnormal functions. Endocrinology 145: 5459–5464.
- 13 Sakamoto A, Chen M, Nakamura T, et al. 2005. Deficiency of the G-protein alpha-subunit G(s)alpha in osteoblasts leads to differential effects on trabecular and cortical bone. J Biol Chem 280: 21369–21375.
- 14 Motomura T, Kasayama S, Takagi M, et al. 1998. Increased interleukin-6 production in mouse osteoblastic MC3T3-E1 cells expressing activating mutant of the stimulatory G protein. J Bone Miner Res 13: 1084–1091.
- 15 Zhong WW, Burke PA, Drotar ME, et al. 1995. Effects of prostaglandin E2, cholera toxin and 8-bromo-cyclic AMP on lipopolysaccharide-induced gene expression of cytokines in human macrophages. Immunology 84: 446–452.
- 16 Drees P, Eckardt A, Gay RE, et al. 2007. Mechanisms of disease: molecular insights into aseptic loosening of orthopedic implants. Nat Clin Pract Rheumatol 3: 165–171.
- 17 Kozasa T, Itoh H, Tsukamoto T, et al. 1998. Isolation and characterization of the human Gs alpha gene. Proc Natl Acad Sci USA 85: 2081–2085.
- 18 Jia H, Hingorani AD, Sharma P, et al. 1999. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 34: 8–14.
- 19 Frey UH, Lummen G, Jager T, et al. 2006. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 12: 759–763.
- 20 Frey UH, Nuckel H, Sellmann L, et al. 2006. The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia. Clin Cancer Res 12: 5686–5692.
- 21 Otterbach F, Callies R, Frey UH, et al. 2007. The T393C polymorphism in the gene GNAS1 of G protein correlates with the clinical course in patients with breast carcinoma. Breast Cancer Res Treat 105: 311–317.
- 22 Yamamoto M, Abe M, Jin JJ, et al. 2004. Association of a GNAS1 gene variant with hypertension and diabetes mellitus. Hypertens Res 27: 919–924.
- 23 Oterino A, Ruiz-Alegria C, Castillo J, et al. 2007. GNAS1 T393C polymorphism is associated with migraine. Cephalalgia 27: 429–434.
- 24 Minoretti P, Politi P, Coen E, et al. 2006. The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample. Neurosci Lett 397: 159–163.
- 25 Yasuda K, Matsunaga T, Moritani T, et al. 2004. T393C polymorphism of GNAS1 associated with the autonomic nervous system in young, healthy Japanese subjects. Clin Exp Pharmacol Physiol 31: 597–601.
- 26 Frey UH, Eisenhardt A, Lummen G, et al. 2005. The T393C polymorphism of the G alpha's gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 14: 871–877.
- 27 Yang W, White B, Spicer EK, et al. 2004. Complex haplotype structure of the human GNAS gene identifies a recombination hotspot centred on a single nucleotide polymorphism widely used in association studies. Pharmacogenetics 14: 741–747.
- 28 Frey UH, Alakus H, Wohlschlaeger J, et al. 2005. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 11: 5071–5077.
- 29 Yang X, Lee FY Sr, Wand GS. 1997. Increased expression of Gs(alpha) enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol 11: 1053–1061.
- 30 Riminucci M, Kuznetsov SA, Cherman N, et al. 2003. Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression. Bone 33: 434–442.
- 31 Neale SD, Sabokbar A, Howie DW, et al. 1999. Macrophage colony-stimulating factor and interleukin-6 release by periprosthetic cells stimulates osteoclast formation and bone resorption. J Orthop Res 17: 686–694.
- 32 Fukayama S, Tashjian AH Jr. 1989. Direct modulation by androgens of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein. Endocrinology 125: 1789–1794.
- 33 Fukayama S, Tashjian AH Jr. 1989. Direct modulation by estradiol of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein. Endocrinology 124: 397–401.
- 34 Tozum TF, Oppenlander ME, Koh-Paige AJ, et al. 2004. Effects of sex steroid receptor specificity in the regulation of skeletal metabolism. Calcif Tissue Int 75: 60–70.
- 35 Neer RM, Arnaud CD, Zanchetta JR, et al. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl J Med 344: 1434–1441.
- 36 Ma YL, Cain RL, Halladay DL, et al. 2001. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142: 4047–4054.
- 37 Irvin BJ, Hanson CL, Smith LH, et al. 2001. Cyclic AMP- and IL6-signaling cross talk: comodulation of proliferation and apoptosis in the 7TD1 B cell hybridoma. Exp Cell Res 265: 73–79.
